calendar
9,060 catalysts · 3,350 8k filing · 1,751 grant · 1,000 device adverse event · 820 approval · 632 device 510k · 584 earnings
next 91 dayslessmore
MonWedFri
9,060 catalysts · 3,350 8k filing · 1,751 grant · 1,000 device adverse event · 820 approval · 632 device 510k · 584 earnings
Supplement type: Real-Time Process. Product code: QON. Advisory committee: GU. Decision: APPR
Supplement type: 30-Day Notice. Product code: MPW. Advisory committee: OR. Decision: OK30
Supplement type: 30-Day Notice. Product code: EZW. Advisory committee: GU. Decision: OK30
Supplement type: 30-Day Notice. Product code: NEK. Advisory committee: OR. Decision: OK30
Supplement type: 30-Day Notice. Product code: NPZ. Advisory committee: DE. Decision: OK30
Supplement type: 30-Day Notice. Product code: SGV. Advisory committee: SU. Decision: OK30
Supplement type: 30-Day Notice. Product code: MOM. Advisory committee: CV. Decision: OK30
Supplement type: 30-Day Notice. Product code: QON. Advisory committee: GU. Decision: OK30
Supplement type: 30-Day Notice. Product code: NGV. Advisory committee: CV. Decision: OK30
AI grant. $427,623. PI: George Kyei
AI grant. $447,604. PI: VICTORIA L ROBINSON
DK grant. $797,878. PI: ROBERTO Ariel GOMEZ
GM grant. $422,677. PI: Valerie Cortez
NR grant. $472,950. PI: Christine March
GM grant. $401,285. PI: Dhiman Ray
ES grant. $415,613. PI: MATTHEW D RAND
AI grant. $624,521. PI: ADRIAN T TING
AI grant. $718,637. PI: Nadejda S Beliakova-Bethell
Sponsor: NOVO. Form: TABLET. Route: ORAL
Sponsor: NOVO. Form: SOLUTION. Route: SUBCUTANEOUS
Sponsor: NOVO. Form: SOLUTION. Route: SUBCUTANEOUS
Sponsor: THEA PHARMA. Form: SOLUTION/DROPS. Route: OPHTHALMIC
Sponsor: ELI LILLY AND CO. Form: SOLUTION. Route: SUBCUTANEOUS
Sponsor: TAKEDA PHARMS USA. Form: INJECTABLE. Route: INJECTION
Sponsor: DR REDDYS. Form: INJECTABLE. Route: INJECTION
Sponsor: APPCO. Form: TABLET. Route: ORAL
Sponsor: RUBICON RESEARCH. Form: SOLUTION. Route: ORAL
Sponsor: SENORES PHARMS. Form: TABLET. Route: ORAL
Sponsor: DR REDDYS LABS LTD. Form: TABLET. Route: ORAL
Sponsor: EUGIA PHARMA. Form: TABLET. Route: ORAL
Sponsor: BEIJING YILING. Form: TABLET. Route: ORAL
Sponsor: RISING. Form: TABLET. Route: ORAL
Sponsor: TAKEDA PHARMS USA. Form: INJECTABLE. Route: INTRAVENOUS
Sponsor: CHIESI. Form: CAPSULE. Route: ORAL
Sponsor: ETON. Form: SOLUTION. Route: ORAL
Sponsor: ALEMBIC. Form: TABLET, ORALLY DISINTEGRATING. Route: ORAL
Product code: FQH. Advisory committee: General Hospital. Type: Special
Product code: OVD. Advisory committee: Orthopedic. Type: Traditional
Product code: ITI. Advisory committee: Physical Medicine. Type: Traditional
Product code: HFX. Advisory committee: Obstetrics/Gynecology. Type: Traditional
Product code: SHI. Advisory committee: Dental. Type: Traditional
Product code: OLO. Advisory committee: Neurology. Type: Special
Product code: PQC. Advisory committee: Orthopedic. Type: Traditional
Supplement type: 30-Day Notice. Product code: NZK. Advisory committee: NE. Decision: OK30
Supplement type: 30-Day Notice. Product code: EZW. Advisory committee: GU. Decision: OK30
Supplement type: 30-Day Notice. Product code: QON. Advisory committee: GU. Decision: OK30
Supplement type: Real-Time Process. Product code: NPS. Advisory committee: CV. Decision: APPR
Supplement type: 30-Day Notice. Product code: MGR. Advisory committee: SU. Decision: OK30
Supplement type: Real-Time Process. Product code: NKM. Advisory committee: CV. Decision: APPR
Supplement type: 30-Day Notice. Product code: SDA. Advisory committee: AN. Decision: OK30